Rapid regression of atherosclerosis: Insights from the clinical and experimental literature

Kevin Jon Williams, Jonathan E. Feig, Edward A. Fisher

Research output: Contribution to journalReview articlepeer-review

173 Scopus citations

Abstract

Looking back at animal and clinical studies published since the 1920s, the notion of rapid regression and stabilization of atherosclerosis in humans has evolved from a fanciful goal to one that might be achievable pharmacologically, even for advanced plaques. Our review of this literature indicates that successful regression of atherosclerosis generally requires robust measures to improve plasma lipoprotein profiles. Examples of such measures include extensive lowering of plasma concentrations of atherogenic apolipoprotein B (apoB)-lipoproteins and enhancement of 'reverse' lipid transport from atheromata into the liver, either alone or in combination. Possible mechanisms responsible for lesion shrinkage include decreased retention of apoB-lipoproteins within the arterial wall, efflux of cholesterol and other toxic lipids from plaques, emigration of foam cells out of the arterial wall, and influx of healthy phagocytes that remove necrotic debris and other components of the plaque. Unfortunately, the clinical agents currently available cause less dramatic changes in plasma lipoprotein levels, and, thereby, fail to stop most cardiovascular events. Hence, there is a clear need for testing of new agents expected to facilitate atherosclerosis regression. Additional mechanistic insights will allow further progress.

Original languageEnglish
Pages (from-to)91-102
Number of pages12
JournalNature Clinical Practice Cardiovascular Medicine
Volume5
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Rapid regression of atherosclerosis: Insights from the clinical and experimental literature'. Together they form a unique fingerprint.

Cite this